Ask The Board

  1. What Geopolitical Issue Are You Paying Closest Attention To?

    See the answer from Carol Nacy, CEO of Sequella, Inc., a private company that develops new anti-infective drugs.

  2. To What Extent Do You Believe That The Combination Of Quality/Relevance Of Products (Or Service), Corporate Culture, And Corporate Values Drives The Successful Integration Of A Company Following A Merger?

    See the answer from Thomas Wiggans, chairman and CEO of Dermira.

  3. What Advice Do You Have For Companies On Building The Science Of Patient Input Into Clinical Trial Development And Execution?

    See the answer from Margaret Anderson, a managing director at Deloitte and previous executive director at FasterCures.

  4. Are The Economics Of Healthcare Delivery Consistent With Classic Theories Of Supply And Demand? It Seems Not When Consumers Are Not The Payers.

    See the answer from Jeff Berkowitz, CEO and director of Real Endpoints, a data/analytics advisory firm.

  5. What Are The Current Trends For Where Compliance Reports In Small To Midsize Life Sciences Companies?

    See the answer from Jason Urban, Ph.D., the head of Celgene’s Business Operational Excellence function.

  6. How Can We Get Away From Blaming Human Error Or Training During The RCA (Root Cause Analysis) Process Of CAPA (Corrective And Preventative Action) And Instead Get To The True Root Of The Issue?

    See the answer from Andrew Skibo, head of global biologics operations & global engineering at MedImmune/AstraZeneca.

  7. How Do You Build A System At A Life Sciences Company That Is “Fit For Purpose”?

    See the answer from Charlene Banard, head of global quality and technical operations at Shire Pharmaceutical. She has more than 25 years of industry experience.

  8. Are Patientless Clinical Trials A Reality Or A Fantasy?

    See the answer from Tomasz Sablinski, MD, Ph.D., cofounder and CEO of Transparency Life Sciences.

  9. What Do You Look For In Board Members/Advisors?

    See the answer from Leslie Williams, president, CEO, and founder of ImmusanT. She has more than 20 years of industry experience.

  10. Where Should Biotech Companies Recruit Scientists For The Future, And How Should Universities Prepare Students To Be The Biotech Workforce For The Future?

    See the answer from Rachel King, CEO of GlycoMimetics, a publically traded biotechnology company. She has nearly 30 years of experience in various management roles in the biotech and pharmaceutical industries.